Guidi Novella, Geiger Hartmut
Institute for Molecular Medicine, Ulm University, Ulm, Germany.
Institute for Molecular Medicine, Ulm University, Ulm, Germany; Division of Experimental Hematology and Cancer Biology, Cincinnati Children׳s Hospital Medical Center, Cincinnati, OH, USA; Aging Research Center, Ulm University, Ulm, Germany.
Semin Hematol. 2017 Jan;54(1):51-55. doi: 10.1053/j.seminhematol.2016.10.005. Epub 2016 Oct 24.
Until recently, there was broad consensus in the stem cell aging field that the phenotype of aged hematopoietic stem cells (HSCs) is fixed-dominated by cell-intrinsic regulatory mechanisms that cannot be altered by pharmacological or genetic means. The conventional thinking was that HSC aging could not be reverted by therapeutic intervention. This paradigm has started to shift dramatically, primarily because hallmarks of aged HSCs have been successfully reverted by distinct experimental approaches by multiple laboratories. We will discuss in this review these hallmarks of HSCs aging and the novel approaches that successfully ameliorated or even reverted aging-associated hallmarks of aged HSCs.
直到最近，干细胞衰老领域仍存在广泛共识，即衰老造血干细胞（HSC）的表型是固定的，由细胞内在调节机制主导，无法通过药理学或遗传学手段改变。传统观点认为，治疗干预无法逆转HSC衰老。这种范式已开始发生巨大转变，主要是因为多个实验室通过不同的实验方法成功逆转了衰老HSC的特征。在本综述中，我们将讨论HSC衰老的这些特征以及成功改善甚至逆转衰老HSC衰老相关特征的新方法。
